N.E.W. Advisory Services’s Eledon Pharmaceuticals ELDN Stock Holding History

N.E.W. Advisory Services’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-626	Closed	-$2.12K	–	859
2025 Q1	$2.12K	Buy	+626	New	+$2.58K	﹤0.01%	785

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

N.E.W. Advisory Services's ELDN Position: Q2 2025 in Review

N.E.W. Advisory Services sold out of Eledon Pharmaceuticals (ELDN) in Q2 2025, closing a stake of 626 shares — an estimated $2.12K sold.

N.E.W. Advisory Services first reported a position in ELDN in Q1 2025 and held it in 1 quarter. The position peaked at $2.12K in Q1 2025. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

N.E.W. Advisory Services reported no remaining Eledon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
N.E.W. Advisory Services sold 626 Eledon Pharmaceuticals shares in Q2 2025, an estimated $2.12K.
N.E.W. Advisory Services first reported a position in Eledon Pharmaceuticals in Q1 2025 and held it in 1 quarter.
N.E.W. Advisory Services's Eledon Pharmaceuticals position peaked at $2.12K in Q1 2025.
85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on N.E.W. Advisory Services's 13F filing for Q2 2025, filed 18 Aug 2025.